Key Points Merck's growth potential is underrated. Novo Nordisk's sell-off has gone too far. Pfizer's story is better than meets the eye. 10 stocks we like better than Merck › The major market indexes are bumping against all-time highs. It's not surprising, therefore, that many stocks are trading at steep valuations. There are, however, some exceptions that are still bargains. Three Motley Fool contributors believe they've found dirt cheap value stocks to buy right now. Here's why they picked Me ...